Law360, New York ( January 9, 2015, 8:56 AM EST) -- On Dec. 5, 2014, the Federal Circuit in Sandoz Inc. v. Amgen Inc. affirmed the district court's dismissal of a declaratory judgment action by Sandoz.[1] Unlike the district court, however, which dismissed the case, in part, based on a statutory interpretation of the Biologics Price Competition and Innovation Act of 2009, the Federal Circuit carefully avoided construing the BPCIA.[2] Instead, the Federal Circuit affirmed dismissal of the case on traditional declaratory judgment grounds, finding "no injury of sufficient immediacy and reality to create subject matter jurisdiction."[3]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.